Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06059638 · ClinicalTrials.gov registry record · NA

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

A NA study of Hypertension and Hypertension,Essential, sponsored by Orchestra BioMed.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
20
Study locations

NCT06059638: Recruiting NA study of Hypertension and Hypertension,Essential, sponsored by Orchestra BioMed.

NCT06059638 is a NA study of Hypertension and Hypertension,Essential that is actively recruiting participants, run by Orchestra BioMed. The registered enrollment target is 500 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06059638, a NA study of Hypertension and Hypertension,Essential, is actively recruiting participants, sponsored by Orchestra BioMed.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.

Primary Outcome

Between group difference in the change of mean 24-hour ambulatory systolic blood pressure (aSBP) from baseline to 3 months post randomization

Interventions

  • DEVICE Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated
  • DEVICE Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated

Study Locations (20)

Florida

  • HCA Florida JFK Hospital - Atlantis
  • Cardiovascular Research Solutions (MyCardiologist) - Celebration
  • Clearwater Cardiovascular Consultants - Clearwater
  • Citrus Cardiology Consultants - Crystal River
  • The Cardiac and Vascular Institute - Gainesville
  • Memorial Healthcare System - Hollywood
  • Baptist Health Jacksonville - Jacksonville
  • Baptist Health South Florida - Miami
  • Mount Sinai Medical Center of Florida - Miami Beach
  • Sarasota Memorial Hospital - Sarasota

California

  • Adventist Health Glendale - Glendale
  • Stanford - Redwood City
  • Scripps Clinic - San Diego
  • Sutter Valley Hospitals - San Francisco

Colorado

  • South Denver Cardiology - Denver
  • Intermountain Health Lutheran Hospital - Golden

Georgia

  • Piedmont Healthcare, Inc. - Atlanta
  • Wellstar Research Institute - Marietta

Arizona

  • HonorHealth - Scottsdale

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2023-12-27
Est. Completion 2029-08
Phase NA
Orchestra BioMed

2 total trials

What NCT06059638 shows while recruiting

NCT06059638 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated is the first listed.

NCT06059638 names 20 study sites across 6 states, led by Florida, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06059638 about?

NCT06059638 is a clinical study titled "BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT". A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.

What is the current status of trial NCT06059638?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2023-12-27. Estimated completion is 2029-08.

What conditions does trial NCT06059638 study?

This clinical trial studies the following conditions: Hypertension, Hypertension,Essential, Hypertension, Systolic.

What interventions are being tested in trial NCT06059638?

The interventions under investigation include: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated (DEVICE), Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated (DEVICE).

Who is sponsoring clinical trial NCT06059638?

This trial is sponsored by Orchestra BioMed, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06059638 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06059638's enrollment target sits among peer trials

500 116th of 470 higher than 349 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06059638, the US trial registry maintained by the National Library of Medicine. NCT06059638 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.